A Phase 2 Open-Label, Multicenter, 4-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Relief of Heartburn, in Adolescent Subjects Aged 12 to 17 Years With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
Latest Information Update: 23 Dec 2021
Price :
$35 *
At a glance
- Drugs Dexlansoprazole (Primary)
- Indications Gastro-oesophageal reflux
- Focus Adverse reactions
- Sponsors Takeda; Takeda Global Research and Development Center
- 02 Nov 2018 Results published in the Digestive Diseases and Sciences
- 15 Sep 2017 Results published in the Digestive Diseases and Sciences
- 22 Jan 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.